MemoBoost

Company Overview

Snapshot

Founded in March 2016 by Prof. Edi Barkai, MemoBoost operates with 1–10 employees. The company has secured funding across one round from Carmel Innovation Fund. In March 2016, MemoBoost announced a new drug treatment approach aimed at inhibiting the onset of dementia.

Business overview

MemoBoost is a Health Tech & Life Sciences company focused on developing a pioneering drug treatment to inhibit the onset of dementia. The company's technology is rooted in research into the scientific foundations of learning and memory in the brain, specifically targeting a receptor in the mGluR family to enhance learning. MemoBoost operates within the Pharmaceuticals sector, serving the Healthcare & Life Sciences market with its drug discovery and development efforts.

Company Intelligence Q&A

What is MemoBoost's primary focus?

MemoBoost is focused on developing a drug treatment designed to inhibit the onset of dementia, based on research into the scientific foundations of learning and memory in the brain.

Who founded MemoBoost?

MemoBoost was founded by Prof. Edi Barkai, who also serves as a researcher for the company.

What is the basis of MemoBoost's technology?

MemoBoost's technology is based on research identifying a specific mGluR family receptor in the brain that, when its excitability is consistently enhanced, improves learning. The company is developing a compound to activate this receptor.

When was MemoBoost founded?

MemoBoost was founded in March 2016.

What is the current status of MemoBoost's operations?

MemoBoost is currently non-active and ceased to operate in May 2024.